Skip to main content
x

Recent articles

ASH 2024 preview – CD19 back on the agenda

Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.

Next for Trodelvy: small-cell lung cancer

Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.

Tango missteps in PRMT5

The company abandons TNG908, but is still all in on the troubled target.

SITC 2024 – Arcus springs a TIGIT surprise

Reports of Arc-10's failure are greatly exaggerated, the company argues.

ASH 2024 preview – Arcellx disappoints

An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.

SITC 2024 preview – duelling TIGIT duds

Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.

Most Popular